Patents by Inventor Tilmann Roos
Tilmann Roos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12318486Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: July 11, 2022Date of Patent: June 3, 2025Assignee: CureVac SEInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 12297489Abstract: The present invention relates to a method for quality control analysis of an RNA sample comprising n different RNA molecule species using reverse transcription and a polymerase chain reaction (PCR) based assay, dPCR, preferably ddPCR, thereby determining at least one quality parameter. Moreover, the RNA molecules in the RNA sample may be in complexed form. In particular, the method is suitable for use in quality control during or following production of RNA samples for pharmaceutical use.Type: GrantFiled: May 17, 2018Date of Patent: May 13, 2025Assignee: CureVac Manufacturing GmbHInventors: Stefan Heinz, Tilmann Roos
-
Patent number: 12208165Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: July 11, 2022Date of Patent: January 28, 2025Assignee: CureVac SEInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 12138348Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: February 21, 2022Date of Patent: November 12, 2024Assignee: CureVac SEInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 11920174Abstract: The present invention relates to analysis of an RNA molecule. It further relates to the use of this method for the quality control of an RNA molecule produced by in vitro transcription or for the quality control of an RNA molecule produced by chemical synthesis.Type: GrantFiled: March 3, 2017Date of Patent: March 5, 2024Assignee: CureVac SEInventors: Fabian Johannes Eber, Aniela Wochner, Tilmann Roos
-
Patent number: 11692002Abstract: The present invention is directed to a method for modifying the retention time of RNA on a chromatographic column. The present invention also concerns a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the present invention provides a method for harmonizing the numbers of A and/or U nucleotides in at least two RNA species. The present invention is also directed to RNA obtainable by said methods, a composition comprising said RNA or a vaccine comprising said RNA and methods for producing such RNA and compositions. Further, the invention concerns a kit, particularly a kit of parts, comprising the RNA, composition or vaccine. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, composition and vaccine.Type: GrantFiled: November 8, 2018Date of Patent: July 4, 2023Assignee: CureVac SEInventors: Stefan Heinz, Tilmann Roos, Dominik Vahrenhorst, Markus Conzelmann
-
Patent number: 11684665Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.Type: GrantFiled: December 22, 2016Date of Patent: June 27, 2023Assignee: CureVac SEInventors: Tilmann Roos, Martin Kunze, Benyamin Yazdan Panah, Salih Yilmaz, Markus Conzelmann
-
Patent number: 11608513Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2?-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2?-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5?-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5?-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2?-O-methyltransferase.Type: GrantFiled: May 30, 2016Date of Patent: March 21, 2023Assignee: CureVac SEInventors: Tilmann Roos, Benyamin Yazdan Panah, Markus Conzelmann, Andreas Thess, Dominik Buob, Martin Kunze, Veronika Wagner
-
Patent number: 11534405Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: June 18, 2020Date of Patent: December 27, 2022Assignee: CureVac AGInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 11525158Abstract: The present invention is concerned with linear double stranded DNA, which is coupled to a single support or a tag at the 3? end of its non-coding strand and methods for producing said linear double stranded DNA. The present invention further relates to the use of said linear double stranded DNA in an RNA in vitro transcription reaction and also to a method for producing RNA in vitro. The present invention also relates to a bioreactor for RNA in vitro transcription.Type: GrantFiled: December 21, 2018Date of Patent: December 13, 2022Assignee: CureVac SEInventors: Benyamin Yazdan Panah, Tilmann Roos, Veronika Wagner, Carola Pongratz
-
Patent number: 11433027Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: August 20, 2020Date of Patent: September 6, 2022Assignee: CureVac AGInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 11384375Abstract: The present invention relates to an immobilized poly(N)polymerase (PNP), methods of producing said PNP and uses thereof. Further disclosed is an enzyme reactor and kit comprising the PNP for producing polynucleotidylated ribonucleic acid poly(N)RNA)molecules which are useful in gene therapy, immunotherapy, protein replacement therapy and/or vaccination.Type: GrantFiled: May 2, 2016Date of Patent: July 12, 2022Assignee: CureVac AGInventors: Tilmann Roos, Benyamin Yazdan Panah, Markus Conzelmann, Veronika Wagner
-
Patent number: 11248223Abstract: The present invention relates to a buffer system comprising a dicarboxylic acid or tricarboxylic acid or a salt thereof for synthesizing RNA molecules as well as a method of RNA in vitro transcription using this buffer system. The present invention also provides the use of this buffer system in RNA in vitro transcription and in the reduction or prevention of precipitates during RNA in vitro transcription.Type: GrantFiled: December 23, 2016Date of Patent: February 15, 2022Assignee: CureVac AGInventors: Benyamin Yazdan Panah, Aniela Wochner, Tilmann Roos, Andreas Funkner, Martin Kunze
-
Patent number: 11179337Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: November 11, 2019Date of Patent: November 23, 2021Assignee: CureVac AGInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 10837039Abstract: The present invention relates to a method for synthesizing an RNA molecule of a given sequence, comprising the step of determining the fraction (1) for each of the four nucleotides G, A, C and U in said RNA molecule, and the step of synthesizing said RNA molecule by in vitro transcription in a sequence-optimized reaction mix, wherein said sequence-optimized reaction mix comprises the four ribonucleoside triphosphates GTP, ATP, CTP and UTP, wherein the fraction (2) of each of the four ribonucleoside triphosphates in the sequence-optimized reaction mix corresponds to the fraction (1) of the respective nucleotide in said RNA molecule, a buffer, a DNA template, and an RNA polymerase.Type: GrantFiled: June 10, 2015Date of Patent: November 17, 2020Assignee: CureVac Real Estate GmbHInventors: Aniela Wochner, Tilmann Roos, Thomas Ketterer
-
Patent number: 10729654Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: May 20, 2016Date of Patent: August 4, 2020Assignee: CureVac AGInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 10517827Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: May 20, 2016Date of Patent: December 31, 2019Assignee: CureVac AGInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewig, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Publication number: 20070031926Abstract: The present invention relates to a method for preparing a solution of a refolded, recombinantly expressed or chemically synthesized eukaryotic membrane protein in monodisperse form, to methods for preparing a crystalline form of a recombinantly expressed or chemically synthesized membrane protein, to a crystalline form of a recombinantly expressed, or chemically synthesized eukaryotic membrane protein, and to a crystalline form of a complex of a recombinantly expressed or chemically synthesized eukaryotic membrane protein and of an accessory agent.Type: ApplicationFiled: June 14, 2006Publication date: February 8, 2007Inventors: Lars Linden, Stefan Prytulla, Thomas Ostermann, Monika Baehner, Tilmann Roos, Andreas Thess, Hans Kiefer, Wolfgang Vogt
-
Publication number: 20050255556Abstract: A method of ion channels folded into their active structure, or functional subunits thereof, is described. For this purpose, initially expressed subunits, which are solubilized and denatured in a first detergent, of an ion channel are provided, and subsequently the first detergent is replaced by a second detergent which induces folding of the subunits of an ion channel into their native structure. The subunits of the ion channel are then assembled into its active structure.Type: ApplicationFiled: April 8, 2005Publication date: November 17, 2005Inventors: Dietrich Loebel, Tilmann Roos, Klaus Maier, Hans Kiefer
-
Publication number: 20050130260Abstract: The present invention relates to a method for preparing a solution of a refolded, recombinantly expressed or chemically synthesized eukaryotic membrane protein in monodisperse form, to methods for preparing a crystalline form of a recombinantly expressed or chemically synthesized membrane protein, to a crystalline form of a recombinantly expressed, or chemically synthesized eukaryotic membrane protein, and to a crystalline form of a complex of a recombinantly expressed or chemically synthesized eukaryotic membrane protein and of an accessory agent.Type: ApplicationFiled: December 15, 2003Publication date: June 16, 2005Inventors: Lars Linden, Stefan Prytulla, Thomas Ostermann, Monika Baehner, Tilmann Roos, Andreas Thess, Hans Kiefer, Wolfgang Vogt